Roche, Biogen Idec, Inc. (Massachusetts) Report One Death In MS Drug Ocrelizumab Phase II Trial

October 18, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

BOSTON, Oct 15 (Reuters) - Roche Holding AG (ROG.VX) and Biogen Idec Inc (BIIB.O) reported data from a mid-stage trial of their experimental multiple sclerosis drug ocrelizumab on Friday that showed one patient died of an inflammatory condition.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 2

Biogen Roche